Accuray's Fiscal 2026 Second Quarter Finances Show Major Organizational Changes Ahead Accuray Incorporated announces its fiscal 2026 second-quarter results, highlighting a strategic transformation plan aimed at enhancing profitability and competitiveness.

Accuray's Fiscal 2026 Second Quarter Finances Show Major Organizational Changes Ahead #USA #financial_results #Madison #Accuray #ARAY

Accuray Unveils Initial Phase of Major Transformation Plan to Boost Profitability and Growth Accuray Incorporated announces the first phase of a strategic plan aimed at improving profitability and fostering growth, with expected $25 million annual gains.

Accuray Unveils Initial Phase of Major Transformation Plan to Boost Profitability and Growth #USA #Madison #Accuray #Transformation #NASDAQ_ARAY

Accuray Unveils Financial Results and Strategic Moves in Fiscal 2026 Quarter One Accuray reports its first quarter financial results for fiscal 2026, announcing leadership changes, restructuring plans, and product innovations.

Accuray Unveils Financial Results and Strategic Moves in Fiscal 2026 Quarter One #USA #Accuray #CyberKnife #Madison,_Wisconsin #Radixact

Accuray Incorporated Announces New CEO Inducement Awards Under NASDAQ Regulations Accuray Incorporated reveals details of equity inducement awards given to new CEO Stephen La Neve, in line with NASDAQ regulations.

Accuray Incorporated Announces New CEO Inducement Awards Under NASDAQ Regulations #United_States #NASDAQ #Madison #Accuray #Stephen_La_Neve

Accuray's Strategic Leadership Changes to Boost Growth and Performance Accuray accelerates its transformation with new executive appointments aimed at enhancing performance and growth in the competitive market of medical technology.

Accuray's Strategic Leadership Changes to Boost Growth and Performance #USA #Madison #medical_technology #Accuray #Steve_La_Neve

Accuray and 5D Clinics Bring Innovative Cancer Treatment to Melbourne with CyberKnife® Accuray and 5D Clinics have initiated the first CyberKnife treatments in Melbourne, revolutionizing cancer care in Australia with advanced technology.

Accuray and 5D Clinics Bring Innovative Cancer Treatment to Melbourne with CyberKnife® #Australia #Melbourne #Accuray #CyberKnife® #5D_Clinics

Accuray Partners with University of Wisconsin to Enhance Cancer Care Through Innovative Radiotherapy Systems Accuray and the University of Wisconsin-Madison have signed an MOU to explore advancements in online adaptive radiotherapy, enhancing personalized cancer treatment and care.

Accuray Partners with University of Wisconsin to Enhance Cancer Care Through Innovative Radiotherapy Systems #USA #Madison #Accuray #Radiotherapy #UW-Madison

Accuray's Major Analyst Event at ASTRO Meeting to Focus on Adaptive Radiotherapy Insights Accuray will hold a pivotal analyst event on September 29, 2025, during the ASTRO Annual Meeting to discuss adaptive radiotherapy developments and perspectives.

Accuray's Major Analyst Event at ASTRO Meeting to Focus on Adaptive Radiotherapy Insights #United_States #San_Francisco #Accuray #Astro #Adaptive_Radiotherapy

Accuray Releases Fourth Quarter and Fiscal Year 2025 Financial Update Accuray Incorporated has shared its financial results for Q4 and fiscal year 2025, showing growth in net revenue despite challenges.

Accuray Releases Fourth Quarter and Fiscal Year 2025 Financial Update #USA #financial_results #Madison #Accuray #Fiscal_2025

Accuray stock tumbles on debt exchange concerns Investing.com -- Shares of Accuray Incorporated (NASDAQ:ARAY) plunged 19.4% as the medical device company announced a complex financing strategy that has raised concerns among investors. The company revealed plans to exchange $82.0 million principal amount of its 3.75% senior convertible notes due 2026 for approximately 8.88 million shares of its common stock, in addition to paying roughly $68.6 million in cash to the holders of the notes. The exchange, slated for completion around June 11, 2025, is contingent on standard closing conditions. In tandem with this exchange, Accuray has entered into a new senior secured credit agreement, securing $150 million in new term loan facilities, a $20 million delayed draw term loan facility, and a $20 million revolving credit facility. The proceeds from these facilities, coupled with available cash, will be used to repay existing debt from a 2021 agreement with Silicon Valley Bank. The financing agreement sets forth an interest rate at the borrower’s option, either a term SOFR-based rate with a 2.00% floor plus a margin of 8.50% or a base rate with a 3.00% floor plus a margin of 7.50%. Up to 6.00% of the interest may be paid in kind, potentially increasing the principal balance of the loans. Accuray’s governance will also see changes, with the appointment of Steven F. Mayer to its Board of Directors as part of a governance agreement with TCW Asset Management Company LLC, the collateral agent and administrative agent for the lenders. Suzanne Winter, president and CEO of Accuray, expressed optimism about the new financing agreement and its alignment with the company’s strategic priorities, which include transforming radiation therapy care and enhancing shareholder value. Winter praised the company’s expanded solution portfolio and anticipated that the new capital structure would improve liquidity and operational flexibility. To further cement the financing agreement, Accuray has issued various warrants to the lenders, with exercise prices ranging from $0.01 to $1.68 and expiration dates in 2032. These warrants include anti-dilution provisions and are subject to certain registration rights. This complex financial restructuring has clearly unsettled investors, as reflected in the significant drop in Accuray’s stock price. The company’s strategic moves aim to strengthen its financial position and support long-term growth, but the immediate market reaction suggests investor apprehension regarding the potential dilution of shares and the cost of the new capital. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Accuray #Stocks #Investing #Finance #DebtExchange

Accuray's Strategic Refocusing Through Convertible Notes Exchange and Credit Facility Refinancing Accuray has announced a significant financial restructuring involving a convertible notes exchange and new credit facilities. This strategic move aims to bolster the company's long-term growth and operational flexibility.

Accuray's Strategic Refocusing Through Convertible Notes Exchange and Credit Facility Refinancing #United_States #Convertible_Notes #Madison #Accuray #Credit_Facilities

Accuray to Present Insights at the Jefferies Global Healthcare Conference 2025 Accuray will take part in the Jefferies Global Healthcare Conference 2025, showcasing its advancements in radiation therapy and engaging with clinicians.

Accuray to Present Insights at the Jefferies Global Healthcare Conference 2025 #USA #healthcare #Madison #Accuray #Radiation_Therapy

Accuray Unveils Groundbreaking Research on 5 Session Radiotherapy for Prostate Cancer at ESTRO 2025 Accuray's latest presentation at ESTRO 2025 highlights the advantages of using the CyberKnife System for prostate cancer treatment, demonstrating its effective outcomes and reduced side effects.

Accuray Unveils Groundbreaking Research on 5 Session Radiotherapy for Prostate Cancer at ESTRO 2025 #USA #Madison #Accuray #Prostate_Cancer #CyberKnife_System

Accuray's PotatoKnife® System Now Treating Patients in Austria: A Leap Forward in Cancer Care #Accuray #Austria #PotatoKnife #Salzburg

Accuray's CyberKnife® System Now Treating Patients in Austria: A Leap Forward in Cancer Care Accuray has introduced its innovative CyberKnife® System at the CyberKnife Center Salzburg, marking a new era in precision cancer treatment in Austria.

Accuray's CyberKnife® System Now Treating Patients in Austria: A Leap Forward in Cancer Care #Accuray #Austria #CyberKnife #Salzburg

Accuray Incorporated Announces Its Financial Results for Q3 FY2025 Highlighting Strong Performance Amid Challenges Accuray Incorporated reports notable growth in Q3 FY2025 financial results, highlighting revenue growth and sharp reduction in net loss, reflecting the company's resilience amidst challenges.

Accuray Incorporated Announces Its Financial Results for Q3 FY2025 Highlighting Strong Performance Amid Challenges #United_States #Madison #Accuray #CyberKnife #ARAY

New Insights on Accuray's CyberKnife® Platform for Treating CNS Tumors Recent studies showcased at the Radiosurgery Society Scientific Meeting reveal the CyberKnife® System's effectiveness in treating CNS tumors. This innovative technology expands treatment options for patients facing limited choices.

New Insights on Accuray's CyberKnife® Platform for Treating CNS Tumors #United_States #Tucson #Accuray #CyberKnife #CNS_Tumors

Accuray to Showcase Innovative Radiation Therapy Solutions at the 37th Annual Roth Conference Accuray Incorporated will actively participate in the upcoming 37th Annual Roth Conference, sharing insights about its transformative radiation therapy technologies and patient care.

Accuray to Showcase Innovative Radiation Therapy Solutions at the 37th Annual Roth Conference #USA #Accuray #Dana_Point #Radiation_Therapy #ROTH_Conference

Accuray Hits Milestone with 100 Patients Treated Using Tomo C System in China Accuray celebrates a significant achievement as Shandong Cancer Hospital completes the treatment of its first 100 patients using the innovative Tomo C Radiation System.

Accuray Hits Milestone with 100 Patients Treated Using Tomo C System in China #China #Cancer_Treatment #Accuray #Tomo_C #Shandong

Leonel Peralta Appointed Chief Operations Officer at Accuray: A New Era for Global Manufacturing Accuray Incorporated announces the appointment of Leonel Peralta as Chief Operations Officer, bringing over 25 years of leadership experience to enhance global operations.

Leonel Peralta Appointed Chief Operations Officer at Accuray: A New Era for Global Manufacturing #USA #Sunnyvale #Accuray #Operations #Leonel_Peralta

Accuray Expands Chinese Product Portfolio with New Approvals for Advanced Radiation Therapy Systems Accuray has gained approval for its Radixact SynC and CyberKnife S7 Systems in China, significantly enhancing treatment options for cancer patients.

Accuray Expands Chinese Product Portfolio with New Approvals for Advanced Radiation Therapy Systems #China #Wisconsin #Accuray #CyberKnife #Radixact

New Findings Highlight CyberKnife System's Role in Treating Challenging Brainstem Metastases Recent research reveals that the CyberKnife System is a promising option for managing brainstem metastases, offering high precision and safety in treatment.

New Findings Highlight CyberKnife System's Role in Treating Challenging Brainstem Metastases #USA #Madison #Accuray #CyberKnife #Radiation_Therapy

Accuray Incorporated: New Inducement Award Sets Stage for Growth under NASDAQ Rules Accuray Incorporated has announced equity inducement awards following NASDAQ rules, aimed at enhancing executive alignment and driving performance through new appointments.

Accuray Incorporated: New Inducement Award Sets Stage for Growth under NASDAQ Rules #USA #NASDAQ #Sunnyvale #Accuray #Mike_Murphy